Targeted-release budesonide for treating primary IgA nephropathy (TA1128)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 February 2026
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (TA1102)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 October 2025
Sparsentan for treating primary IgA nephropathy (TA1074)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 9 October 2025Published: 25 June 2025
Dapagliflozin for treating chronic kidney disease (TA1075)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 July 2025
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2025
Empagliflozin for treating chronic kidney disease (TA942)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Difelikefalin for treating pruritus in people having haemodialysis (TA890)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 May 2023
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 May 2023
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2023
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 July 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
Chronic kidney disease: assessment and management (NG203)Product type:GuidanceProgramme:NICE guidelineLast updated: 24 November 2021Published: 25 August 2021
Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (HTG530)Product type:GuidanceProgramme:HealthTech guidancePublished: 13 November 2019
Renal replacement therapy and conservative management (NG107)Product type:GuidanceProgramme:NICE guidelinePublished: 3 October 2018
Immunosuppressive therapy for kidney transplant in adults (TA481)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)Product type:GuidanceProgramme:HealthTech guidancePublished: 21 June 2017
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2015
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 January 2009
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007